Impact in Healthcare
The specific strain RHT3201, here known as LR, may potentially confer benefits to pediatric patients with AD to relieve symptoms, based on low certainty of evidence. Although the effect did not reach clinical significance, further research on the optimal dose and duration of treatment using LR may be explored. LR showed favorable safety outcomes based on moderate certainty of evidence. As the age of the participants in the trials included for this study are considerably broad, suggestions on the optimal age for postbiotic administration in AD treatment cannot be made.